Skip to main content
. 2016 Nov 26;8(32):52256–52268. doi: 10.18632/oncotarget.13665

Figure 4. Correlation between 5-hmc level and TET expression and impact on survival.

Figure 4

(A, B) Correlation between the level of TET2 (A) or TET3 (B) transcript and the level of genomic 5-hmc. Both acute (open circle) and chronic (closed circle) patients were considered for the analysis. (C) Survival of acute and chronic ATLL patients. Survival probabilities were estimated by the log-rank (Mantel-Cox) test. Median survival was 5.3 and 63 months for acute and chronic patients, respectively. (D) Survival of ATLL patients (acute and chronic) according to the level of TET2 transcript. The threshold of 1.2 corresponds to the mean TET2 expression of the selected patients. Median survival was 6.9 and 49.5 months for acute and chronic patients, respectively. (E) Survival of ATLL patients (acute and chronic) according to the level of TET3 transcript. The threshold of 1.2 corresponds to the mean TET3 expression of the selected patients. Median survival was 7.75 and 28.7 months for acute and chronic patients, respectively. (F) Survival of ATLL patients (acute and chronic) according to the level of 5-hmc. The threshold of 0.3 corresponds to the mean 5-hmc values of the selected patients. Median survival was 4.8 and 36 months for acute and chronic patients, respectively. Patient details are presented in Supplementary Table S1.